Cyprumed GmbH, a drug delivery company specializing in oral peptide formulations and Merck, known as MSD outside the U.S., have signed a Non-Exclusive License and Option Agreement to develop oral formulations of MSD’s peptides using Cyprumed’s innovative drug delivery technology. Under the terms of the agreement, MSD gained non-exclusive global rights to Cyprumed’s oral peptide delivery platform for an undisclosed number of targets. The agreement also grants MSD the option to exclusively lice...